http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015266552-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate | 2015-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a8074e094b5ef20c1320a359e552342 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f79a5af60a7680fa1131ed95b8b1716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14e1a292139819481d9ba093fc64bdc8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c6c6f45753d31046b41a27520eeb456 |
| publicationDate | 2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2015266552-A1 |
| titleOfInvention | Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient |
| abstract | [Problem] To provide a medicinal composition for treating cancer in which at least one kinase selected from among BTK, JAK3 and ITK participates. [Solution] As the results of studies on compounds having BTK inhibiting effect, JAK3 inhibiting effect and ITK inhibiting effect, the present inventors confirmed that specific pyrazine carboxamide compounds have BTK inhibiting effect, JAK3 inhibiting effect and ITK inhibiting effect, and medicinal compositions comprising these compounds as an active ingredient have therapeutic effect on cancers in which at least one kinase selected from among BTK, JAK3 and ITK participates, cancers in which BTK is overexpressed or activated in another embodiment, cancers in which B cell receptor signals are activated in a still another embodiment, cancers in which JAK3 is activation-mutated or activated in a still another embodiment, and cancers in which ITK is activated in a still another embodiment, thereby completing the present invention. |
| priorityDate | 2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.